Based in ‘s-Hertogenbosch, Immunovo BV specializes in the discovery and clinical development of immunotherapeutics for cancer treatment. Their main focus lies in their proprietary Immune Activation System (IAS), which combines synthetic peptide antigens with a unique immune stimulant (adjuvant). By leveraging this technology, Immunovo aims to create innovative pharmaceutical products that can effectively combat cancer through immunotherapy in the field of oncology.